Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: OSTEOPOROSIS, POSTMENOPAUSAL - DRUG THERAPY , . Treffer: 28

2017

Bone, HG; Wagman, RB; Brandi, ML; Brown, JP; Chapurlat, R; Cummings, SR; Czerwiński, E; Fahrleitner-Pammer, A; Kendler, DL; Lippuner, K; Reginster, JY; Roux, C; Malouf, J; Bradley, MN; Daizadeh, NS; Wang, A; Dakin, P; Pannacciulli, N; Dempster, DW; Papapoulos, S 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Lancet Diabetes Endocrinol. 2017; 5(7):513-523
Web of Science PubMed FullText FullText_MUG

 

Diez-Perez, A; Naylor, KE; Abrahamsen, B; Agnusdei, D; Brandi, ML; Cooper, C; Dennison, E; Eriksen, EF; Gold, DT; Guañabens, N; Hadji, P; Hiligsmann, M; Horne, R; Josse, R; Kanis, JA; Obermayer-Pietsch, B; Prieto-Alhambra, D; Reginster, JY; Rizzoli, R; Silverman, S; Zillikens, MC; Eastell, R; Adherence Working Group of the International Osteoporosis Foundation and the European Calcified Tissue Society International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates.
Osteoporos Int. 2017; 28(3):767-774 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Fahrleitner-Pammer, A; Papaioannou, N; Gielen, E; Feudjo Tepie, M; Toffis, C; Frieling, I; Geusens, P; Makras, P; Boschitsch, E; Callens, J; Anastasilakis, AD; Niedhart, C; Resch, H; Kalouche-Khalil, L; Hadji, P Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
Arch Osteoporos. 2017; 12(1):58-58 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Paschalis, EP; Gamsjaeger, S; Hassler, N; Fahrleitner-Pammer, A; Dobnig, H; Stepan, JJ; Pavo, I; Eriksen, EF; Klaushofer, K Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality.
Bone. 2017; 95(2):41-46
Web of Science PubMed FullText FullText_MUG

 

2016

Fahrleitner-Pammer, A; Burr, D; Dobnig, H; Stepan, JJ; Petto, H; Li, J; Krege, JH; Pavo, I Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment.
Bone. 2016; 89(6):16-24 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2015

Hadji, P; Papaioannou, N; Gielen, E; Feudjo Tepie, M; Zhang, E; Frieling, I; Geusens, P; Makras, P; Resch, H; Möller, G; Kalouche-Khalil, L; Fahrleitner-Pammer, A Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Osteoporos Int. 2015; 26(10):2479-2489 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2014

Hofstetter, B; Gamsjaeger, S; Varga, F; Dobnig, H; Stepan, JJ; Petto, H; Pavo, I; Klaushofer, K; Paschalis, EP Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.
Osteoporos Int. 2014; 25(12):2709-2719
Web of Science PubMed FullText FullText_MUG

 

Ma, YL; Zeng, QQ; Chiang, AY; Burr, D; Li, J; Dobnig, H; Fahrleitner-Pammer, A; Michalská, D; Marin, F; Pavo, I; Stepan, JJ Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment.
Bone. 2014; 59(5):139-147
Web of Science PubMed FullText FullText_MUG

 

Muschitz, C; Kocijan, R; Fahrleitner-Pammer, A; Pavo, I; Haschka, J; Schima, W; Kapiotis, S; Resch, H Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
J Bone Miner Res. 2014; 29(8):1777-1785 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Roux, C; Hofbauer, LC; Ho, PR; Wark, JD; Zillikens, MC; Fahrleitner-Pammer, A; Hawkins, F; Micaelo, M; Minisola, S; Papaioannou, N; Stone, M; Ferreira, I; Siddhanti, S; Wagman, RB; Brown, JP Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Bone. 2014; 58(2):48-54 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2013

Kerschan-Schindl, K; Haschka, J; Obermayer-Pietsch, B; Gasser, RW; Dimai, HP; Fahrleitner-Pammer, A; Dobnig, H; Roschger, P; Preisinger, E; Klaushofer, K; Resch, H; Pietschmann, P How long should women with postmenopausal osteoporosis be treated with a bisphosphonate?
Horm Metab Res. 2013; 45(9):621-628
Web of Science PubMed FullText FullText_MUG

 

Muschitz, C; Kocijan, R; Fahrleitner-Pammer, A; Lung, S; Resch, H Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
J Bone Miner Res. 2013; 28(1):196-205 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2012

Jakob, F; Oertel, H; Langdahl, B; Ljunggren, O; Barrett, A; Karras, D; Walsh, JB; Fahrleitner-Pammer, A; Rajzbaum, G; Barker, C; Lems, WF; Marin, F Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study.
Eur J Endocrinol. 2012; 166(1):87-97 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Karras, D; Stoykov, I; Lems, WF; Langdahl, BL; Ljunggren, ; Barrett, A; Walsh, JB; Fahrleitner-Pammer, A; Rajzbaum, G; Jakob, F; Marin, F Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study.
J Rheumatol. 2012; 39(3):600-609
Web of Science PubMed FullText FullText_MUG

 

Muschitz, C; Fahrleitner-Pammer, A; Huber, J; Preisinger, E; Kudlacek, S; Resch, H Update on denosumab in postmenopausal osteoporosis--recent clinical data.
Wien Med Wochenschr. 2012; 162(17-18):374-379
PubMed FullText FullText_MUG

 

2011

Quesada-Gómez, JM; Muschitz, C; Gómez-Reino, J; Greisen, H; Andersen, HS; Dimai, HP The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial.
Osteoporos Int. 2011; 22(9): 2529-2537.
Web of Science PubMed FullText FullText_MUG

 

2010

Dimai, HP; Pietschmann, P; Resch, H; Preisinger, E; Fahrleitner-Pammer, A; Dobnig, H; Klaushofer, K; Austrian Society for Bone and Mineral Research (AuSBMR) Austrian guidance for the pharmacologic treatment of osteoporosis in postmenopausal women: Addendum 2010].
Wien Med Wochenschr. 2010; 160(21-22):586-589
PubMed FullText FullText_MUG

 

Stepan, JJ; Burr, DB; Li, J; Ma, YL; Petto, H; Sipos, A; Dobnig, H; Fahrleitner-Pammer, A; Michalská, D; Pavo, I Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
Osteoporos Int. 2010; 21(12): 2027-2036.
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2009

Cummings, SR; San Martin, J; McClung, MR; Siris, ES; Eastell, R; Reid, IR; Delmas, P; Zoog, HB; Austin, M; Wang, A; Kutilek, S; Adami, S; Zanchetta, J; Libanati, C; Siddhanti, S; Christiansen, C; FREEDOM Trial Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
N Engl J Med. 2009; 361(8): 756-765. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Dimai, HP; Pietschmann, P; Resch, H; Preisinger, E; Fahrleitner-Pammer, A; Dobnig, H; Klaushofer, K; Austrian Society for Bone and Mineral Research (AuSBMR) Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009
Wien Med Wochenschr Suppl. 2009; (122): 1-34.
PubMed FullText FullText_MUG Google Scholar

 

Eastell, R; Nickelsen, T; Marin, F; Barker, C; Hadji, P; Farrerons, J; Audran, M; Boonen, S; Brixen, K; Gomes, JM; Obermayer-Pietsch, B; Avramidis, A; Sigurdsson, G; Glüer, CC Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).
J Bone Miner Res. 2009; 24(4): 726-736. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2008

Boonen, S; Marin, F; Obermayer-Pietsch, B; Simões, ME; Barker, C; Glass, EV; Hadji, P; Lyritis, G; Oertel, H; Nickelsen, T; McCloskey, EV; for the EUROFORS Investigators Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
J Clin Endocrinol Metab. 2008; 93(3):852-860 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Minne, H; Audran, M; Simões, ME; Obermayer-Pietsch, B; Sigurðsson, G; Marín, F; Dalsky, GP; Nickelsen, T; EUROFORS Study Group Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study.
Curr Med Res Opin. 2008; 24(11):3117-3128 [Keynote lecture]
Web of Science PubMed FullText FullText_MUG

 

2007

Stepan, JJ; Burr, DB; Pavo, I; Sipos, A; Michalska, D; Li, J; Fahrleitner-Pammer, A; Petto, H; Westmore, M; Michalsky, D; Sato, M; Dobnig, H Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis.
Bone. 2007; 41(3): 378-385.
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2005

Dobnig, H; Sipos, A; Jiang, Y; Fahrleitner-Pammer, A; Ste-Marie, LG; Gallagher, JC; Pavo, I; Wang, J; Eriksen, EF Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy.
J Clin Endocrinol Metab. 2005; 90(7):3970-3977 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2004

Rásky, E Evidence based basis of decision making for or against a postmenopausal hormone treatment
Wien Klin Wochenschr. 2004; 116(14):461-464
Web of Science PubMed

 

2002

Reid, IR; Brown, JP; Burckhardt, P; Horowitz, Z; Richardson, P; Trechsel, U; Widmer, A; Devogelaer, JP; Kaufman, JM; Jaeger, P; Body, JJ; Brandi, ML; Broell, J; Di Micco, R; Genazzani, AR; Felsenberg, D; Happ, J; Hooper, MJ; Ittner, J; Leb, G; Mallmin, H; Murray, T; Ortolani, S; Rubinacci, A; Saaf, M; Samsioe, G; Verbruggen, L; Meunier, PJ Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
N Engl J Med. 2002; 346(9):653-661 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

1998

Masaryk, P; Lunt, M; Benevolenskaya, L; Cannata, J; Dequeker, J; Dohenhof, C; Falch, JA; Felsenberg, D; Pols, HA; Poor, G; Reid, DM; Scheidt-Nave, C; Weber, K; O'Neill, T; Silman, AJ; Reeve, J Effects of menstrual history and use of medications on bone mineral density: the EVOS Study.
Calcif Tissue Int. 1998; 63(4):271-276
Web of Science PubMed FullText FullText_MUG Google Scholar

 

© Meduni Graz Impressum